What is HC Scientific?
Founded in 2016 and headquartered in the Chengdu Tianfu International Bio-city, HC Scientific specializes in the development and manufacturing of high-throughput automated molecular detection equipment. The company operates at the intersection of advanced engineering and life sciences, aiming to streamline complex diagnostic workflows. Its core mission centers on empowering life science technology through precision instrumentation, effectively reducing the barriers to high-volume molecular analysis. By providing robust, automated solutions, HC Scientific serves as a critical infrastructure provider for institutions engaged in health management and drug discovery, positioning itself as a key innovator within the rapidly evolving Chinese biotechnology landscape.
How much funding has HC Scientific raised?
HC Scientific has raised a total of $41.2M across 1 funding round:
Series B
$41.2M
Series B (2023): $41.2M with participation from Guotai Junan Securities, Lake Bleu Capital, Dalton Venture, Chengdu Tianfu International Bio-Town Investment & Development, and Eightfold AI
Key Investors in HC Scientific
Guotai Junan Securities
A leading Chinese financial services firm providing comprehensive investment banking and capital market solutions to institutional and individual clients.
Lake Bleu Capital
A prominent healthcare-focused investment platform in Asia, specializing in both public equity and mid-to-late-stage private equity within the life sciences sector.
Dalton Venture
A venture capital entity dedicated to early-stage investments and industrial mergers in the health sector, emphasizing innovative medical technologies and services.
What's next for HC Scientific?
With the successful closure of this major enterprise-level funding round, HC Scientific is strategically positioned to scale its manufacturing capabilities and expand its international market presence. The company is expected to prioritize the refinement of its automated detection systems, ensuring they meet the rigorous demands of global medical testing and pharmaceutical R&D environments. Furthermore, the strategic alignment with its diverse investor base provides not only the necessary liquidity for R&D acceleration but also access to deep industry expertise in healthcare and financial services. Moving forward, the firm will likely focus on deepening its integration within the global life science supply chain, leveraging its technological edge to capture a larger share of the molecular diagnostics market while maintaining its commitment to operational excellence and innovation.
See full HC Scientific company page
